HomeAI · summaries
Storia in 2 fonti
Chinese cancer treatment shows survival edge in trial
Chinese biotech firm Akeso Inc has announced positive interim results from a registrational Phase-3 trial, showing that its home-grown bispecific antibody ivonescimab combined with chemotherapy delivers statistically significant and clinically meaningful overall-survival benefits for patients with advanced biliary-tract cancer, compared with durvalumab plus chemotherapy.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary…
Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary…
- ·
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in…
